Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of levetiracetam 3D printing preparation and preparation method thereof

A 3D printing and preparation technology, applied in the field of levetiracetam 3D printing preparation and its preparation, levetiracetam 3D printing tablet, levetiracetam tablet such as levetiracetam dispersible tablet, It can solve the problems of insufficient mechanical properties such as surface roughness, hardness, and friability of the tablet, failure to coordinate the rapid disintegration and smooth appearance of the tablet, and the rough appearance of the rapidly dispersing tablet, so as to improve drug compliance and improve drug use. Experience and reduce the effect of dosage differences

Active Publication Date: 2021-11-30
ACADEMY OF MILITARY MEDICAL SCI
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the appearance of the rapidly dispersible tablet prepared by this invention is rough, which fails to coordinate the requirements of rapid disintegration and smooth appearance of the tablet, and cannot realize the printing of a dispersible tablet with a good appearance, especially a delicate cartoon tablet.
[0012] The biggest defect of binder jet 3D printing is the appearance of the product. Due to the stacking of different polymers and powders, surface defects of the product may appear, such as insufficient mechanical properties such as tablet surface roughness, hardness, and friability. Affect patients' medication experience and may even cause dosage differences due to surface powder falling during tablet storage and transportation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of levetiracetam 3D printing preparation and preparation method thereof
  • A kind of levetiracetam 3D printing preparation and preparation method thereof
  • A kind of levetiracetam 3D printing preparation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0142] Preparation Example 1: Preparation of Sample 1-1, Sample 1-2, Sample 1-3 and Sample 1-4

[0143] 1. Preparation of drug powder

[0144]Levetiracetam is pulverized through a 120-mesh sieve, colloidal silicon dioxide is passed through a 40-mesh sieve, and the remaining auxiliary materials are passed through a 120-mesh sieve. Add the raw and auxiliary materials into the hopper mixer, set the speed at 20 rpm, and mix for 20 minutes to ensure that the drug powder is evenly mixed. The drug powder material composition is as follows:

[0145]

[0146] 2. Preparation of printing solution

[0147] A 50% ethanol solution (v / v) was used as base solvent.

[0148] The composition of each printing solution is as follows:

[0149] (1) Transparent printing fluid:

[0150] 50% ethanol solution 95.95% (w / w)

[0151] Povidone K30 0.05% (w / w)

[0152] Glycerin 4% (w / w)

[0153] (2) Cyan printing solution (C):

[0154]

[0155]

[0156] (3) Magenta printing solution (M): ...

preparation example 2

[0174] Preparation Example 2: Preparation of Sample 2-1, Sample 2-2, Sample 2-3 and Sample 2-4

[0175] 1. Preparation of drug powder

[0176] Levetiracetam is pulverized through a 120-mesh sieve, colloidal silicon dioxide is passed through a 40-mesh sieve, and the remaining auxiliary materials are passed through a 120-mesh sieve. Add the raw and auxiliary materials into the hopper mixer, set the speed at 20 rpm, and mix for 20 minutes to ensure that the drug powder is evenly mixed. The drug powder material composition is as follows:

[0177]

[0178] 2. Preparation of printing solution

[0179] A 40% isopropanol solution (v / v) was used as base solvent.

[0180] The composition of each printing solution is as follows:

[0181] (1) Transparent printing fluid:

[0182] 40% isopropanol solution 95.9% (w / w)

[0183] Povidone K30 0.1% (w / w)

[0184] Glycerin 4% (w / w)

[0185] (2) Cyan printing solution (C):

[0186]

[0187]

[0188] (3) Magenta printing solutio...

preparation example 3

[0207] Preparation Example 3: Preparation of Sample 3-1, Sample 3-2, Sample 3-3 and Sample 3-4

[0208] 1. Preparation of drug powder

[0209] With preparation example 2.

[0210] 2. Preparation of printing solution

[0211] With preparation example 2.

[0212] 3. Model design

[0213] With preparation example 1.

[0214] 4. Tablet printing

[0215] Transfer the model data to the 3D printer control software, set the printing quantity and typesetting, and the printing parameters are set as follows:

[0216]

[0217]

[0218] First, spread a certain thickness of drug powder on the printing platform, as a support for the bottom of the printing model and ensure that a single powder layer can be spread evenly during the printing process. The thickness of the powder layer is 2-5mm. During the printing process, the thickness of each powder layer is 150 μm. The print nozzle finely sprays a certain number of droplets on a specific part according to the instructions input ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
heightaaaaaaaaaa
heightaaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of medicines and preparations, and relates to a levetiracetam 3D printing preparation and a preparation method thereof. Specifically, the present invention relates to a levetiracetam 3D printing preparation, including levetiracetam accounting for 40%-70% of the weight of the preparation, as well as fillers, disintegrants, flavoring agents, glidants, anti- Oxygen and binder; wherein, the roughness characteristic value root mean square height (Sq) of the levetiracetam 3D printing preparation is not higher than 45 μm, the arithmetic mean height (Sa) is not higher than 40 μm, and the maximum height ( Sz) is not higher than 350 μm. The preparation of the invention has excellent surface smoothness, can realize rapid drug release within a few seconds, can realize flexible adjustment of drug dosage, and greatly improves children's drug compliance.

Description

technical field [0001] The invention belongs to the field of medicines and preparations, and relates to a levetiracetam 3D printing preparation and a preparation method thereof. Specifically, the present invention relates to a levetiracetam tablet such as levetiracetam dispersible tablet, and a method for preparing the levetiracetam tablet such as levetiracetam dispersible tablet using 3D printing technology . In particular, it relates to 3D printed tablets of levetiracetam suitable for administration to children. Background technique [0002] Levetiracetam is a pyrrolidone derivative and one of the most widely used broad-spectrum antiepileptic drugs in clinical practice. Levetiracetam is easily soluble and highly permeable, rapidly absorbed after oral administration, with an absolute bioavailability close to 100%, linear metabolism, small intra-individual and inter-individual differences, no gender, racial or circadian rhythm differences. Due to the complete and linear a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/44A61K47/38A61K47/32A61K31/4015A61P25/08B33Y70/10B33Y80/00
CPCA61K9/2072A61K9/2095A61K9/2054A61K9/2027A61K31/4015A61P25/08B33Y70/10B33Y80/00
Inventor 郑爱萍王增明陈如心韩晓璐张慧高静刘楠高翔
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products